Bicara Therapeutics Inc
BCAX15.980USD
-0.270-1.66%
收盘 11/03, 16:00（美东）报价延迟15分钟
871.81M总市值
亏损市盈率 TTM
关于 Bicara Therapeutics Inc 公司
Bicara Therapeutics Inc. 是一家临床阶段的生物制药公司，致力于为实体瘤患者提供变革性的双功能疗法。其主要项目 ficerafusp alfa 是一种双功能抗体，结合了两个经过临床验证的靶点，即表皮生长因子受体 (EGFR)，定向单克隆抗体与与人转化生长因子β (TGF-b) 结合的结构域。通过这种双重靶向机制，ficerafusp alfa 有可能通过同时阻断癌细胞内在的 EGFR 存活和增殖以及肿瘤微环境中的免疫抑制 TGF-b 信号传导来发挥强大的抗肿瘤活性。ficerafusp alfa 最初是在头颈部鳞状细胞癌中开发的，该领域仍存在大量未满足的需求。其平台旨在促进双功能疗法的开发，这些疗法可精确靶向肿瘤并将调节肿瘤的有效载荷递送到肿瘤部位。
Bicara Therapeutics Inc简介
公司代码BCAX
公司名称Bicara Therapeutics Inc
上市日期Sep 13, 2024
CEODr. Claire Mazumdar, Ph.D.
员工数量55
证券类型Ordinary Share
年结日Sep 13
公司地址116 Huntington Avenue, Suite 703
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编02116
电话16174684219
网址https://www.bicara.com/
公司代码BCAX
上市日期Sep 13, 2024
CEODr. Claire Mazumdar, Ph.D.
Bicara Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
198.14K
-10.40%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Vijay Kuchroo, Ph.D.
Dr. Vijay Kuchroo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Kiran Mazumdar Shaw
Dr. Kiran Mazumdar Shaw
Independent Director
Independent Director
--
--
Mr. Scott Robertson
Mr. Scott Robertson
Independent Director
Independent Director
--
--
Ms. Kate Haviland
Ms. Kate Haviland
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
309.89K
--
Dr. Ryan Cohlhepp, Pharm.D.
Dr. Ryan Cohlhepp, Pharm.D.
President, Chief Operating Officer
President, Chief Operating Officer
198.14K
-10.40%
Mr. Ivan Hyep
Mr. Ivan Hyep
Chief Financial Officer
Chief Financial Officer
145.35K
--
Dr. Nils Lonberg, Ph.D.
Dr. Nils Lonberg, Ph.D.
Independent Director
Independent Director
29.99K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
--
--
Dr. David Raben, M.D.
Dr. David Raben, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
RA Capital Management, LP
12.75%
Biocon Ltd.
10.12%
Invus Public Equities Advisors, LLC
9.56%
Vestal Point Capital, LP
9.16%
Red Tree Management, LLC
5.81%
其他
52.59%
持股股东
持股股东
占比
RA Capital Management, LP
12.75%
Biocon Ltd.
10.12%
Invus Public Equities Advisors, LLC
9.56%
Vestal Point Capital, LP
9.16%
Red Tree Management, LLC
5.81%
其他
52.59%
股东类型
持股股东
占比
Investment Advisor
38.31%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
17.76%
Corporation
10.77%
Hedge Fund
10.22%
Private Equity
7.26%
Research Firm
1.44%
Individual Investor
1.42%
Pension Fund
0.16%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
204
51.57M
94.51%
-222.49K
2025Q2
189
57.62M
105.65%
+8.16M
2025Q1
183
53.15M
97.51%
+4.06M
2024Q4
149
51.31M
94.30%
+11.56M
2024Q3
80
39.83M
80.65%
+39.83M
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RA Capital Management, LP
6.96M
12.75%
--
--
Jun 30, 2025
Biocon Ltd.
5.52M
10.12%
+5.41M
+4671.98%
Apr 14, 2025
Invus Public Equities Advisors, LLC
5.22M
9.56%
+1.95M
+59.68%
Jun 30, 2025
Vestal Point Capital, LP
5.00M
9.16%
+2.23M
+80.57%
Jun 30, 2025
Red Tree Management, LLC
3.17M
5.81%
--
--
Jun 30, 2025
TPG Capital, L.P.
3.01M
5.52%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
2.54M
4.65%
-1.07M
-29.71%
Jun 30, 2025
Deep Track Capital LP
2.43M
4.45%
+426.66K
+21.33%
Jun 30, 2025
Omega Fund Management, LLC
2.20M
4.04%
--
--
Jun 30, 2025
T. Rowe Price Associates, Inc.
2.12M
3.88%
+344.02K
+19.41%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
Hypatia Women CEO ETF
0.25%
Fidelity Enhanced Small Cap ETF
0.06%
T Rowe Price Small-Mid Cap ETF
0.05%
iShares Russell 2000 Value ETF
0.04%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
iShares Russell 2000 ETF
0.02%
Global X Russell 2000 ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.98%
ALPS Medical Breakthroughs ETF
占比0.51%
Hypatia Women CEO ETF
占比0.25%
Fidelity Enhanced Small Cap ETF
占比0.06%
T Rowe Price Small-Mid Cap ETF
占比0.05%
iShares Russell 2000 Value ETF
占比0.04%
JPMorgan BetaBuilders US Small Cap Equity ETF
占比0.03%
ProShares Hedge Replication ETF
占比0.02%
iShares Russell 2000 ETF
占比0.02%
Global X Russell 2000 ETF
占比0.02%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
